Pfizer Inc. (LON:0Q1N)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 107.84B +11.5% |
| Revenue (ttm) | 47.64B +1.4% |
| Net Income | 5.64B -5.0% |
| EPS | 0.99 -5.1% |
| Shares Out | n/a |
| PE Ratio | 19.13 |
| Forward PE | 8.68 |
| Dividend | 1.28 (5.10%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 102,398 |
| Open | 25.26 |
| Previous Close | 25.23 |
| Day's Range | 24.96 - 25.38 |
| 52-Week Range | 21.83 - 28.88 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer's experimental drug misses main goal of lung cancer trial
Pfizer said on Monday its drug for a type of lung cancer missed the main goal of a late-stage trial.
Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint
Pfizer (PFE) announced topline results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 directed antibody-drug conjugate (A...
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigationa...
Pfizer (PFE) Shares Sink After Surprise CFO Exit
Pfizer Inc. ($PFE) fell 2.7% on Thursday after the company disclosed that Chief Financial Officer Dave Denton will step down on August 15. The share price decline pushed the stock…
Pfizer reaffirms all components of FY26 guidance
Following the disclosure of Pfizer’s (PFE) CFO transition announcement on June 18, 2026, Pfizer is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first…
Pfizer CFO Dave Denton to step down, Cecile Guegan named interim CFO
Pfizer (PFE) announced that Dave Denton, CFO, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry…
Pfizer CFO Dave Denton to step down, leave company in August
Pfizer said on Thursday that finance chief Dave Denton will step down and leave the company on August 15 to take a role in the consumer goods industry.
Pfizer Announces Chief Financial Officer Transition
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional...
Pfizer CEO warns German investment at risk over drug pricing policies
Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter to Chancellor Friedrich Merz, citing the government's policy proposals that would low...
Pfizer upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital upgraded Pfizer (PFE) to Sector Perform from Underperform with a $25 price target
Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward
RBC Capital analyst Trung Huynh upgraded Pfizer (PFE) to Sector Perform from Underperform with a $25 price target The firm notes that its overall thesis has not changed substantially on…
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Consistent financial outperformance and strategic transformation have positioned the business for growth beyond COVID, with a diversified pipeline in oncology, obesity, and immunology. AI and China are seen as key industry disruptors, while upcoming product launches and strong M&A execution support a high single-digit revenue CAGR from 2029.
Pfizer says FDA approves expanded indication for Hympavzi
Pfizer (PFE) announced that the U.S. FDA has approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years and older with…
US FDA approves Pfizer's bleeding disorder drug for children
The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of bleeding episodes in children and in certain patients with hemophilia, the company said on Mond...
U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the ...
Pfizer presents results from Phase 2b studies of berobenatide
Pfizer (PFE) presented detailed results from multiple Phase 2b studies of berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide, during a late-breaking expe...
Pfizer Transcript: Study update
Phase IIb data show monthly berobenatide achieves weight loss comparable to weekly tirzepatide and potentially better than semaglutide, with strong GI tolerability and a patient-friendly dosing profile. Ten Phase III trials are advancing, including studies for obesity, comorbidities, and combination therapies.
Pfizer Slides: Study update
Pfizer has posted slides in relation to its latest quarterly earnings report, which was published on June 6, 2026.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nor...
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential first-in-class monthly GLP-1...
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the company engineering AI models to discover new molecules, announces a license agreement with Pfizer.